West Cancer Center

MELANOMA: PHASE 1: TOLL-LIKE RECEPTOR AGONIST AB CONJUGATE: INCLINE-101

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Title

Tallac Incline-101 phase I metastatic solid tumors

Study Title

A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Site Link

NCT05399654

Malignancy

Melanoma

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

Any

Investigational Agent

TAC-001

Drug Class

T-cell receptor agonist antibody drug conjugate

Dan Vaena, MD

Sponsor

Tallac Pharmaceuticals

Phase

Phase 1

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

CURRENTLY ONLY THE MELANOMA COHORT IS ENROLLING

Inclusion Criteria:

Exclusion Criteria:

Prior history of or active malignant disease other than that being treated in this study.
Known brain metastases or cranial epidural disease.
A known hypersensitivity to the components of the study therapy or its' analogs.

Objective

Primary:

Secondary

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Histologic documentation

Dosing Frequency

Control Agents

Study Protocol

Randomized